Special Focus Content: Epithelial-mesenchymal transition in tumor metastasis: a method to the madness - Review

Department of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA

^*Both authors are equal contributors to this work.

Department of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA

^*Both authors are equal contributors to this work.

† Author for correspondence

Department of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Room L18–6110, 12801 East 17th Avenue, PO Box 6511, Aurora, CO 80045, USA.

Search for more papers by this author

Email the corresponding author at Bill.Schiemann@ucdenver.edu

Published Online:26 Oct 2009https://doi.org/10.2217/fon.09.90

View article

Abstract

The formation of epithelial cell barriers results from the defined spatiotemporal differentiation of stem cells into a specialized and polarized epithelium, a process termed mesenchymal–epithelial transition. The reverse process, epithelial–mesenchymal transition (EMT), is a metastable process that enables polarized epithelial cells to acquire a motile fibroblastoid phenotype. Physiological EMT also plays an essential role in promoting tissue healing, remodeling or repair in response to a variety of pathological insults. On the other hand, pathophysiological EMT is a critical step in mediating the acquisition of metastatic phenotypes by localized carcinomas. Although metastasis clearly is the most lethal aspect of cancer, our knowledge of the molecular events that govern its development, including those underlying EMT, remain relatively undefined. Transforming growth factor-β (TGF-β) is a multifunctional cytokine that oversees and directs all aspects of cell development, differentiation and homeostasis, as well as suppresses their uncontrolled proliferation and transformation. Quite dichotomously, tumorigenesis subverts the tumor suppressing function of TGF-β, and in doing so, converts TGF-β to a tumor promoter that stimulates pathophysiological EMT and metastasis. It therefore stands to reason that determining how TGF-β induces EMT in developing neoplasms will enable science and medicine to produce novel pharmacological agents capable of preventing its ability to do so, thereby improving the clinical course of cancer patients. Here we review the cellular, molecular and microenvironmental mechanisms used by TGF-β to mediate its stimulation of EMT in normal and malignant cells.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

1 Baum B, Settleman J, Quinlan MP: Transitions between epithelial and mesenchymal states in development and disease. Semin. Cell Dev. Biol.19,294–308 (2008).
Medline CASGoogle Scholar
2 Yang J, Weinberg RA: Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell.14,818–829 (2008).
Medline CASGoogle Scholar
3 Elenbaas B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res.264,169–184 (2001).
Medline CASGoogle Scholar
4 Moustakas A, Heldin CH: Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci.98,1512–1520 (2007).
Medline CASGoogle Scholar
5 Zavadil J, Bottinger EP: TGF-β and epithelial-to-mesenchymal transitions. Oncogene24,5764–5774 (2005).
Medline CASGoogle Scholar
6 Thiery JP: Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol.15,740–746 (2003).
Medline CASGoogle Scholar
7 Shook D, Keller R: Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development. Mech. Dev.120,1351–1383 (2003).
Medline CASGoogle Scholar
8 Thiery JP: Epithelial–mesenchymal transitions in tumor progression. Nat. Rev. Cancer2,442–454 (2002).
Medline CASGoogle Scholar
9 Willis BC, Borok Z: TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol.293,L525–L534 (2007).
Medline CASGoogle Scholar
10 Blobe GC, Schiemann WP, Lodish HF: Role of TGF-β in human disease. N. Engl. J. Med.342,1350–1358 (2000).
Medline CASGoogle Scholar
11 Galliher AJ, Neil JR, Schiemann WP: Role of TGF-β in cancer progression. Future Oncol.2,743–763 (2006).
CASGoogle Scholar
12 Massague J, Gomis RR: The logic of TGF-β signaling. FEBS Lett.580,2811–2820 (2006).
Medline CASGoogle Scholar
13 Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer3,807–821 (2003).
Medline CASGoogle Scholar
14 Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial–mesenchymal transition. Bioessays23,912–923 (2001).
Medline CASGoogle Scholar
15 Miettinen PJ, Ebner R, Lopez AR, Derynck R: TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol.127,2021–2036 (1994).
Medline CASGoogle Scholar
16 Kaartinen V, Voncken JW, Shuler C et al.: Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial–mesenchymal interaction. Nature Genet.11,415–421 (1995).▪ Study established the critical role for transforming growth factor (TGF)-β3 in regulating developmental epithelial–mesenchymal transition (EMT).
Medline CASGoogle Scholar
17 Romano LA, Runyan RB: Slug is an essential target of TGF-β2 signaling in the developing chicken heart. Dev. Biol.223,91–102 (2000).
Medline CASGoogle Scholar
18 Saika S, Kono-Saika S, Ohnishi Y et al.: Smad3 signaling is required for epithelial–mesenchymal transition of lens epithelium after injury. Am. J. Pathol.164,651–663 (2004).
Medline CASGoogle Scholar
19 Saika S, Kono-Saika S, Tanaka T et al.: Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab. Invest.84,1245–1258 (2004).
Medline CASGoogle Scholar
20 Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest.112,1486–1494 (2003).
Medline CASGoogle Scholar
21 Feng XH, Derynck R: Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol.21,659–693 (2005).
Medline CASGoogle Scholar
22 Moustakas A, Heldin CH: Non-Smad TGF-β signals. J. Cell Sci.118,3573–3584 (2005).
Medline CASGoogle Scholar
23 Shi Y, Massague J: Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell113,685–700 (2003).
Medline CASGoogle Scholar
24 Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE domain protein that recruits Smad2 to the TGF-β receptor. Cell95,779–791 (1998).▪ Identified sarA as a novel adapter molecule that facilitates Smad2/3 recruitment and activation by TGF-β receptors.
Medline CASGoogle Scholar
25 Miura S, Takeshita T, Asao H et al.: Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol. Cell Biol.20,9346–9355 (2000).
Medline CASGoogle Scholar
26 Hocevar BA, Smine A, Xu XX, Howe PH: The adaptor molecule Disabled-2 links the TGF-β receptors to the Smad pathway. EMBO J.20,2789–2801 (2001).
Medline CASGoogle Scholar
27 Hayashi H, Abdollah S, Qiu Y et al.: The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell89,1165–1173 (1997).▪ Identified Smad7 as an inhibitory molecule of the TGF-β signaling system.
Medline CASGoogle Scholar
28 Nakao A, Afrakht M, Moren A et al.: Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature389,631–635 (1997).▪ Identified Smad7 as an inhibitory molecule of the TGF-β signaling system.
Medline CASGoogle Scholar
29 Souchelnytskyi S, Nakayama T, Nakao A et al.: Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and TGF-β receptors. J. Biol. Chem.273,25364–25370 (1998).
Medline CASGoogle Scholar
30 Ebisawa T, Fukuchi M, Murakami G et al.: Smurf1 interacts with TGF-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem.276,12477–12480 (2001).
Medline CASGoogle Scholar
31 Kavsak P, Rasmussen RK, Causing CG et al.: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol. Cell6,1365–1375 (2000).
Medline CASGoogle Scholar
32 Datta PK, Moses HL: STRAP and Smad7 synergize in the inhibition of TGF-β signaling. Mol. Cell. Biol.20,3157–3167 (2000).
Medline CASGoogle Scholar
33 Ibarrola N, Kratchmarova I, Nakajima D et al.: Cloning of a novel signaling molecule, AMSH-2, that potentiates TGF-β signaling. BMC Cell Biol.5,2 (2004).
MedlineGoogle Scholar
34 Koinuma D, Shinozaki M, Komuro A et al.: Arkadia amplifies TGF-β superfamily signalling through degradation of Smad7. EMBO J.22,6458–6470 (2003).
Medline CASGoogle Scholar
35 Liu FY, Li XZ, Peng YM, Liu H, Liu YH: Arkadiα-SMAd7-mediated positive regulation of TGF-β signaling in a rat model of tubulointerstitial fibrosis. Am. J. Nephrol.27,176–183 (2007).
MedlineGoogle Scholar
36 Liu W, Rui H, Wang J et al.: Axin is a scaffold protein in TGF-β signaling that promotes degradation of Smad7 by Arkadia. EMBO J.25,1646–1658 (2006).
Medline CASGoogle Scholar
37 Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL: p38 mitogen-activated protein kinase is required for TGF-β-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci.115,3193–3206 (2002).
Medline CASGoogle Scholar
38 Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL: Phosphatidylinositol 3-kinase function is required for TGF-β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem.275,36803–36810 (2000).
Medline CASGoogle Scholar
39 Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL: Integrin β1 signaling is necessary for TGF-β activation of p38MAPK and epithelial plasticity. J. Biol. Chem.276,46707–46713 (2001).
Medline CASGoogle Scholar
40 Lamouille S, Derynck R: Cell size and invasion in TGF-β induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol.178,437–451 (2007).
Medline CASGoogle Scholar
41 Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA: TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol.3,708–714 (2001).
Medline CASGoogle Scholar
42 Zavadil J, Bitzer M, Liang D et al.: Genetic programs of epithelial cell plasticity directed by TGF-β. Proc. Natl Acad. Sci. USA98,6686–6691 (2001).
Medline CASGoogle Scholar
43 Galliher AJ, Schiemann WP: β3 integrin and Src facilitate TGF-β mediated induction of epithelial–mesenchymal transition in mammary epithelial cells. Breast Cancer Res.8,R42 (2006).
MedlineGoogle Scholar
44 Galliher AJ, Schiemann WP: Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res.67,3752–3758 (2007).
Medline CASGoogle Scholar
45 Galliher-Beckley AJ, Schiemann WP: Grb2 binding to Tyr284 in TGF-β is essential for mammary tumor growth and metastasis stimulated by TGF-β. Carcinogenesis29,244–251 (2008).
Medline CASGoogle Scholar
46 Azuma M, Motegi K, Aota K, Yamashita T, Yoshida H, Sato M: TGF-β1 inhibits NF-κB activity through induction of IκBα expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-β1. Exp. Cell Res.250,213–222 (1999).
Medline CASGoogle Scholar
47 Neil JR, Schiemann WP: Altered TAB1:IkB kinase interaction promotes TGF-β-mediated NF-κB activation during breast cancer progression. Cancer Res.68,1462–1470 (2008).▪ Together with [37–42], established various noncanonical TGF-β effectors as critical mediators of EMT and oncogenic signaling stimulated by TGF-β.
Medline CASGoogle Scholar
48 Arsura M, Panta GR, Bilyeu JD et al.: Transient activation of NF-κB through a TAK1//IKK kinase pathway by TGF-β1 inhibits AP-1//SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene22,412–425 (2003).
Medline CASGoogle Scholar
49 Kim DW, Sovak MA, Zanieski G et al.: Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis21,871–879 (2000).
MedlineGoogle Scholar
50 Park J-I, Lee M-G, Cho K et al.: TGF-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene22,4314–4332 (2003).
Medline CASGoogle Scholar
51 Rayet B, Gelinas C: Aberrant Rel/NF-κB genes and activity in human cancer. Oncogene18,6938–6947 (1999).
Medline CASGoogle Scholar
52 Horowitz JC, Rogers DS, Sharma V et al.: Combinatorial activation of FAK and AKT by TGF-β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal.19,761–771 (2007).
Medline CASGoogle Scholar
53 Thannickal VJ, Lee DY, White ES et al.: Myofibroblast differentiation by TGF-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem.278,12384–12389 (2003).
Medline CASGoogle Scholar
54 Park SS, Eom YW, Kim EH et al.: Involvement of c-Src kinase in the regulation of TGF-β1-induced apoptosis. Oncogene23,6272–6281 (2004).
Medline CASGoogle Scholar
55 Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J.19,1–11 (2005).
MedlineGoogle Scholar
56 Wilkes MC, Leof EB: TGF-β activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J. Biol. Chem.281,27846–27854 (2006).
Medline CASGoogle Scholar
57 Ebnet K, Suzuki A, Ohno S, Vestweber D: Junctional adhesion molecules (JAMs): more molecules with dual functions? J. Cell Sci.117,19–29 (2004).
Medline CASGoogle Scholar
58 Schneeberger EE, Lynch RD: The tight junction: a multifunctional complex. Am. J. Physiol. Cell. Physiol.286,C1213–C1228 (2004).
Medline CASGoogle Scholar
59 Itoh M, Bissell MJ: The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J. Mammary Gland Biol. Neoplasia8,449–462 (2003).
MedlineGoogle Scholar
60 Bose R, Wrana JL: Regulation of Par6 by extracellular signals. Curr. Opin. Cell Biol.18,206–212 (2006).
Medline CASGoogle Scholar
61 Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL: Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity. Science307,1603–1609 (2005).▪ Identified the novel interaction between Par6 and TGF-β receptors, which promote EMT via the ubiquitination and degradation of RhoA.
Medline CASGoogle Scholar
62 Takaishi K, Sasaki T, Kotani H, Nishioka H, Takai Y: Regulation of cell–cell adhesion by Rac and Rho small G proteins in MDCK Cells. J. Cell Biol.139,1047–1059 (1997).
Medline CASGoogle Scholar
63 Niessen CM: Tight junctions/adherens junctions: basic structure and function. J. Invest. Dermatol.127,2525–2532 (2007).
Medline CASGoogle Scholar
64 Ridley AJ, Hall A: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell70,389–399 (1992).
Medline CASGoogle Scholar
65 Bhowmick NA, Ghiassi M, Bakin A et al.: TGF-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell12,27–36 (2001).
Medline CASGoogle Scholar
66 Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer4,839–849 (2004).
Medline CASGoogle Scholar
67 Kaplan RN, Rafii S, Lyden D: Preparing the ‘soil’: the premetastatic niche. Cancer Res.66,11089–11093 (2006).
Medline CASGoogle Scholar
68 Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu. Rev. Pathol.1,119–150 (2006).
Medline CASGoogle Scholar
69 Park CC, Bissell MJ, Barcellos-Hoff MH: The influence of the microenvironment on the malignant phenotype. Mol. Med. Today6,324–329 (2000).
Medline CASGoogle Scholar
70 Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2,161–174 (2002).
Medline CASGoogle Scholar
71 Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol.16,558–564 (2004).
Medline CASGoogle Scholar
72 Duivenvoorden WC, Hirte HW, Singh G: TGF-β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin. Exp. Metastasis17,27–34 (1999).
Medline CASGoogle Scholar
73 Kim ES, Sohn YW, Moon A: TGF-β-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Lett.252,147–156 (2007).
Medline CASGoogle Scholar
74 Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell103,481–490 (2000).
Medline CASGoogle Scholar
75 Paszek MJ, Weaver VM: The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland Biol. Neoplasia.9,325–342 (2004).
MedlineGoogle Scholar
76 Anderson AR, Weaver AM, Cummings PT, Quaranta V: Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell127,905–915 (2006).▪ Very interesting study that used a multiscale mathematical modeling approach to predict how altered microenvironmental factors and conditions impact tumor development and progression.
Medline CASGoogle Scholar
77 Sternlicht MD, Bissell MJ, Werb Z: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene19,1102–1113 (2000).
Medline CASGoogle Scholar
78 Sternlicht MD, Lochter A, Sympson CJ et al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell98,137–146 (1999).▪ Established the essential role of matrix metalloproteinases (MMPs) in regulating the interactions between cells and their microenvironments, and in stimulating EMT.
Medline CASGoogle Scholar
79 Radisky DC, Levy DD, Littlepage LE et al.: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature436,123–127 (2005).▪ Established the essential role of matrix metalloproteinases (MMPs) in regulating the interactions between cells and their microenvironments, and in stimulating EMT.
Medline CASGoogle Scholar
80 Radisky DC, Kenny PA, Bissell MJ: Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J. Cell Biochem.101,830–839 (2007).
Medline CASGoogle Scholar
81 Huber MA, Kraut N, Beug H: Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr. Opin. Cell Biol.17,548–558 (2005).
Medline CASGoogle Scholar
82 Gotzmann J, Mikula M, Eger A et al.: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat. Res.566,9–20 (2004).
Medline CASGoogle Scholar
83 Jechlinger M, Grunert S, Beug H: Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. J. Mammary Gland Biol. Neoplasia7,415–432 (2002).
MedlineGoogle Scholar
84 Cavallaro U, Niedermeyer J, Fuxa M, Christofori G: N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol.3,650–657 (2001).
Medline CASGoogle Scholar
85 Lehembre F, Yilmaz M, Wicki A et al.: NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J.27,2603–2615 (2008).
Medline CASGoogle Scholar
86 Illman SA, Lehti K, Keski-Oja J, Lohi J: Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells. J. Cell Sci.119,3856–3865 (2006).
Medline CASGoogle Scholar
87 Illman SA, Lohi J, Keski-Oja J: Epilysin (MMP-28) – structure, expression and potential functions. Exp. Dermatol.17,897–907 (2008).
Medline CASGoogle Scholar
88 Harbeck N, Kates RE, Schmitt M et al.: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer5,348–352 (2004).
Medline CASGoogle Scholar
89 Duffy MJ, Duggan C: The urokinase plasminogen activator system: a rich source of tumor markers for the individualized management of patients with cancer. Clin. Biochem.37,541–548 (2004).
Medline CASGoogle Scholar
90 Mitra SK, Lim ST, Chi A, Schlaepfer DD: Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngenetic tumor model. Oncogene25,4429–4440 (2006).
Medline CASGoogle Scholar
91 Lin SW, Ke FC, Hsiao PW, Lee PP, Lee MT, Hwang JJ: Critical involvement of ILK in TGF-β1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system. Exp. Cell Res.313,602–613 (2007).
Medline CASGoogle Scholar
92 Lester RD, Jo M, Montel V, Takimoto S, Gonias SL: uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol.178,425–436 (2007).
Medline CASGoogle Scholar
93 Santibanez JF: JNK mediates TGF-β1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes. FEBS Lett.580,5385–5391 (2006).
Medline CASGoogle Scholar
94 Whitley BR, Church FC: Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1. Int. J. Oncol.27,749–757 (2005).
Medline CASGoogle Scholar
95 Binder BR, Christ G, Gruber F et al.: Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol. Sci.17,56–61 (2002).
Medline CASGoogle Scholar
96 Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS: Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J. Biol. Chem.283,19570–19580 (2008).
Medline CASGoogle Scholar
97 Kortlever RM, Bernards R: Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle5,2697–2703 (2006).
Medline CASGoogle Scholar
98 Whitley BR, Palmieri D, Twerdi CD, Church FC: Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp. Cell Res.296,151–162 (2004).
Medline CASGoogle Scholar
99 Descotes F, Riche B, Saez S et al.: Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin. Breast Cancer8,168–177 (2008).
MedlineGoogle Scholar
100 Wienke D, Davies GC, Johnson DA et al.: The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res.67,10230–10240 (2007).
Medline CASGoogle Scholar
101 Kim ES, Kim MS, Moon A: TGF-β in conjunction with H-Ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine29,84–91 (2005).
Medline CASGoogle Scholar
102 Ignotz RA, Massague J: TGF-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem.261,4337–4345 (1986).
Medline CASGoogle Scholar
103 Xie L, Law B, Aakre M et al.: TGF-β-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res.5,R187–R198 (2003).
Medline CASGoogle Scholar
104 Maschler S, Wirl G, Spring H et al.: Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene24,2032–2041 (2005).
Medline CASGoogle Scholar
105 Kang Y, Massague J: Epithelial–mesenchymal transitions: Twist in development and metastasis. Cell118,277–279 (2004).
Medline CASGoogle Scholar
106 Bremnes RM, Veve R, Hirsch FR, Franklin WA: The E-cadherin cell–cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer36,115–124 (2002).
MedlineGoogle Scholar
107 Graff JR, Greenberg VE, Herman JG et al.: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma. Cancer Res.58,2063–2066 (1998).
Medline CASGoogle Scholar
108 Comijn J, Berx G, Vermassen P et al.: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell7,1267–1278 (2001).
Medline CASGoogle Scholar
109 Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer7,415–428 (2007).
Medline CASGoogle Scholar
110 Cano A, Perez-Moreno MA, Rodrigo I et al.: The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol.2,76–83 (2000).
Medline CASGoogle Scholar
111 Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A: TGF-β employs HMGA2 to elicit epithelial–mesenchymal transition. J. Cell Biol.174,175–183 (2006).
Medline CASGoogle Scholar
112 Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol.148,779–790 (2000).
Medline CASGoogle Scholar
113 Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res.13,7003–7011 (2007).
Medline CASGoogle Scholar
114 Pyo SW, Hashimoto M, Kim YS et al.: Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. J. Craniomaxillofac. Surg.35,1–9 (2007).
MedlineGoogle Scholar
115 Yang L, Huang J, Ren X et al.: Abrogation of TGF-β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell.13,23–35 (2008).
Medline CASGoogle Scholar
116 Nam JS, Terabe M, Mamura M et al.: An anti-TGF-β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res.68,3835–3843 (2008).
Medline CASGoogle Scholar
117 Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol.4,657 (2003).
MedlineGoogle Scholar
118 Masszi A, Di Ciano C, Sirokmany G et al.: Central role for Rho in TGF-β1-induced α-smooth muscle actin expression during epithelial–mesenchymal transition. Am. J. Physiol. Renal Physiol.284,F911–F924 (2003).
Medline CASGoogle Scholar
119 Yazhou C, Wenlv S, Weidong Z, Licun W: Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol.25,290–295 (2004).
MedlineGoogle Scholar
120 Cary LA, Guan JL: Focal adhesion kinase in integrin-mediated signaling. Front. Biosci.4,D102–D113 (1999).
Medline CASGoogle Scholar
121 Cary LA, Han DC, Guan JL: Integrin-mediated signal transduction pathways. Histol. Histopathol.14,1001–1009 (1999).
Medline CASGoogle Scholar
122 Schwartz MA, Ginsberg MH: Networks and crosstalk: integrin signalling spreads. Nat. Cell Biol.4,E65–E68 (2002).
Medline CASGoogle Scholar
123 Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer.2,91–100 (2002).
MedlineGoogle Scholar
124 Ginsberg MH, Partridge A, Shattil SJ: Integrin regulation. Curr. Opin. Cell Biol.17,509–516 (2005).
Medline CASGoogle Scholar
125 Guo W, Giancotti FG: Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol.5,816–826 (2004).
Medline CASGoogle Scholar
126 Sieg DJ, Hauck CR, Ilic D et al.: FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol.2,249–256 (2000).
Medline CASGoogle Scholar
127 Chen SY, Chen HC: Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol. Cell. Biol.26,5155–5167 (2006).
Medline CASGoogle Scholar
128 Mizejewski GJ: Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med.222,124–138 (1999).
Medline CASGoogle Scholar
129 Sheppard D, Cohen DS, Wang A, Busk M: TGF-β differentially regulates expression of integrin subunits in guinea pig airway epithelial cells. J. Biol. Chem.267,17409–17414 (1992).
Medline CASGoogle Scholar
130 Kumar NM, Sigurdson SL, Sheppard D, Lwebuga-Mukasa JS: Differential modulation of integrin receptors and extracellular matrix laminin by TGF-β1 in rat alveolar epithelial cells. Exp. Cell Res.221,385–394 (1995).
Medline CASGoogle Scholar
131 Wang A, Yokosaki Y, Ferrando R, Balmes J, Sheppard D: Differential regulation of airway epithelial integrins by growth factors. Am. J. Respir. Cell Mol. Biol.15,664–672 (1996).
Medline CASGoogle Scholar
132 Munger JS, Huang X, Kawakatsu H et al.: The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell96,319–328 (1999).▪ First established the importance of integrins in promoting the activation of latent TGF-β complexes.
Medline CASGoogle Scholar
133 Jenkins RG, Su X, Su G et al.: Ligation of protease-activated receptor 1 enhances αvβ6 integrin-dependent TGF-β activation and promotes acute lung injury. J. Clin. Invest.116,1606–1614 (2006).
Medline CASGoogle Scholar
134 Neurohr C, Nishimura SL, Sheppard D: Activation of TGF-β by the integrin αvβ8 delays epithelial wound closure. Am. J. Respir. Cell Mol. Biol.35,252–259 (2006).
Medline CASGoogle Scholar
135 Morris DG, Huang X, Kaminski N et al.: Loss of integrin αvβ6-mediated TGF-β activation causes MMP12-dependent emphysema. Nature422,169–173 (2003).
Medline CASGoogle Scholar
136 Mu D, Cambier S, Fjellbirkeland L et al.: The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J. Cell Biol.157,493–507 (2002).
Medline CASGoogle Scholar
137 Knight PA, Wright SH, Brown JK, Huang X, Sheppard D, Miller HR: Enteric expression of the integrin αvβ6 is essential for nematode-induced mucosal mast cell hyperplasia and expression of the granule chymase, mouse mast cell protease-1. Am. J. Pathol.161,771–779 (2002).
Medline CASGoogle Scholar
138 Kim KK, Kugler MC, Wolters PJ et al.: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA103,13180–13185 (2006).
Medline CASGoogle Scholar
139 Bates RC, Bellovin DI, Brown C et al.: Transcriptional activation of integrin β6 during the epithelial–mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest.115,339–347 (2005).
Medline CASGoogle Scholar
140 Ma LJ, Yang H, Gaspert A et al.: TGF-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6(-/-) mice. Am. J. Pathol.163,1261–1273 (2003).
Medline CASGoogle Scholar
141 Owens DM, Broad S, Yan X, Benitah SA, Watt FM: Suprabasal α5β1 integrin expression stimulates formation of epidermal squamous cell carcinomas without disrupting TGF-β signaling or inducing spindle cell tumors. Mol. Carcinog.44,60–66 (2005).
Medline CASGoogle Scholar
142 Kostenuik PJ, Singh G, Orr FW: TGF-β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin. Exp. Metastasis15,41–52 (1997).
Medline CASGoogle Scholar
143 Giannelli G, Fransvea E, Marinosci F et al.: TGF-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin. Am. J. Pathol.161,183–193 (2002).
Medline CASGoogle Scholar
144 Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S: Laminin-5 with TGF-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology129,1375–1383 (2005).
Medline CASGoogle Scholar
145 Sloan EK, Pouliot N, Stanley KL et al.: Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res.8,R20 (2006).
MedlineGoogle Scholar
146 Bandyopadhyay A, Agyin JK, Wang L et al.: Inhibition of pulmonary and skeletal metastasis by a TGF-β type I receptor kinase inhibitor. Cancer Res.66,6714–6721 (2006).
Medline CASGoogle Scholar
147 Nakamura K, Yano H, Schaefer E, Sabe H: Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial–mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies. Oncogene20,2626–2635 (2001).
Medline CASGoogle Scholar
148 Liu S, Shi-wen X, Kennedy L et al.: FAK is required for TGF-β-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol. Biol. Cell.18,2169–2178 (2007).
Medline CASGoogle Scholar
149 Cicchini C, Laudadio I, Citarella F et al.: TGF-β-induced EMT requires focal adhesion kinase (FAK) signaling. Exp. Cell Res.314,143 (2008).
Medline CASGoogle Scholar
150 Wendt MK, Schiemann WP: Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Res.11(5),R68 (2009).
MedlineGoogle Scholar
151 Kim W, Seok Kang Y, Soo Kim J, Shin N-Y, Hanks SK, Song WK: The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in TGF-β signaling. Mol. Biol. Cell.19,2135–2146 (2008).
Medline CASGoogle Scholar
152 Cabodi S, Tinnirello A, Di Stefano P et al.: p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-Neu oncogene-dependent breast tumorigenesis. Cancer Res.66,4672–4680 (2006).
Medline CASGoogle Scholar
153 Tumbarello DA, Brown MC, Hetey SE, Turner CE: Regulation of paxillin family members during epithelial–mesenchymal transformation: a putative role for paxillin δ. J. Cell Sci.118,4849–4863 (2005).
Medline CASGoogle Scholar
154 Fujimoto N, Yeh S, Kang HY et al.: Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem.274,8316–8321 (1999).
Medline CASGoogle Scholar
155 Guerrero-Santoro J, Yang L, Stallcup MR, DeFranco DB: Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation. J. Cell Biochem.92,810–819 (2004).
Medline CASGoogle Scholar
156 Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR: Interaction of the Tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol. Biol. Cell.11,2007–2018 (2000).
Medline CASGoogle Scholar
157 Tumbarello DA, Turner CE: Hic-5 contributes to epithelial–mesenchymal transformation through a RhoA/ROCK-dependent pathway. J. Cell Physiol.211,736–747 (2007).
Medline CASGoogle Scholar
158 Mok SC, Wong KK, Chan RK et al.: Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol. Oncol.52,247–252 (1994).
Medline CASGoogle Scholar
159 Mok SC, Chan WY, Wong KK et al.: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene16,2381–2387 (1998).
Medline CASGoogle Scholar
160 Prunier C, Hocevar BA, Howe PH: Wnt signaling: physiology and pathology. Growth Factors22,141–150 (2004).
Medline CASGoogle Scholar
161 Prunier C, Howe PH: Disabled-2 (Dab2) is required for TGF-β-induced epithelial to mesenchymal transition (EMT). J. Biol. Chem.280,17540–17548 (2005).
Medline CASGoogle Scholar
162 Hocevar BA, Prunier C, Howe PH: Disabled-2 (Dab2) mediates TGF-β-stimulated fibronectin synthesis through TGF-β-activated kinase 1 and activation of the JNK pathway. J. Biol. Chem.280,25920–25927 (2005).
Medline CASGoogle Scholar
163 Sorrentino A, Thakur N, Grimsby S et al.: The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol.10,1199–1207 (2008).▪ Demonstrates the importance of TRAF6 to interact physically with TGF-β receptors, leading to the activation of MAP kinases via ubiquitination of TAK1.
Medline CASGoogle Scholar
164 Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol. Cell31,918–924 (2008).▪ Demonstrates the importance of TRAF6 to interact physically with TGF-β receptors, leading to the activation of MAP kinases via ubiquitination of TAK1.
Medline CASGoogle Scholar
165 Gal A, Sjoblom T, Fedorova L, Imreh S, BeugH, Moustakas A: Sustained TGF-β exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene27,1218–1230 (2008).
Medline CASGoogle Scholar
166 Hall A: Rho GTPases and the control of cell behaviour. Biochem. Soc. Trans.33,891–895 (2005).
Medline CASGoogle Scholar
167 Hall A, Nobes CD: Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos. Trans. R. Soc. Lond. B. Biol. Sci.355,965–970 (2000).
Medline CASGoogle Scholar
168 Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J. Cell Biol.147,1009–1022 (1999).
Medline CASGoogle Scholar
169 Cho HJ, Yoo J: Rho activation is required for TGF-β-induced epithelial–mesenchymal transition in lens epithelial cells. Cell Biol. Int.31,1225–1230 (2007).
Medline CASGoogle Scholar
170 Massague J: How cells read TGF-β signals. Nat. Rev. Mol. Cell. Biol.1,169–178 (2000).
Medline CASGoogle Scholar
171 Murillo MM, del Castillo G, Sanchez A, Fernandez M, Fabregat I: Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes. Oncogene24,4580–4587 (2005).
Medline CASGoogle Scholar
172 Jechlinger M, Sommer A, Moriggl R et al.: Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest.116,1561–1570 (2006).
Medline CASGoogle Scholar
173 Dedhar S, Williams B, Hannigan G: Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends. Cell Biol.9,319–323 (1999).
Medline CASGoogle Scholar
174 Hannigan G, Troussard AA, Dedhar S: Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer.5,51–63 (2005).
Medline CASGoogle Scholar
175 Hehlgans S, Haase M, Cordes N: Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta.1775,163–180 (2007).
Medline CASGoogle Scholar
176 White DE, Cardiff RD, Dedhar S, Muller WJ: Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene20,7064–7072 (2001).
Medline CASGoogle Scholar
177 Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD: Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J. Cell Sci.114,1125–1136 (2001).
Medline CASGoogle Scholar
178 Lee YI, Kwon YJ, Joo CK: Integrin-linked kinase function is required for TGF-β-mediated epithelial to mesenchymal transition. Biochem. Biophys. Res. Commun.316,997–1001 (2004).
Medline CASGoogle Scholar
179 Karin M: NF-κB in cancer development and progression. Nature441,431 (2006).
Medline CASGoogle Scholar
180 Huber MA, Azoitei N, Baumann B et al.: NF-κB is essential for epithelial–mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest.114,569–581 (2004).
Medline CASGoogle Scholar
181 Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H: NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene26,711 (2006).
MedlineGoogle Scholar
182 Sovak MA, Arsura M, Zanieski G, Kavanagh KT, Sonenshein GE: The inhibitory effects of TGF-β1 on breast cancer cell proliferation are mediated through regulation of aberrant NF-κB/Rel expression. Cell Growth Differ.10,537–544 (1999).
Medline CASGoogle Scholar
183 Neil JR, Johnson KM, Nemenoff RA, Schiemann WP: Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-β through a PGE2-dependent mechanisms. Carcinogenesis29,2227–2235 (2008).
Medline CASGoogle Scholar
184 Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL: Activation of the ERK pathway is required for TGF-β1-induced EMT in vitro. Neoplasia6,603–610 (2004).
Medline CASGoogle Scholar
185 Atfi A, Djelloul S, Chastre E, Davis R, Gespach C: Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in TGF-β-mediated signaling. J. Biol. Chem.272,1429–1432 (1997).
Medline CASGoogle Scholar
186 Hocevar BA, Brown TL, Howe PH: TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J.18,1345–1356 (1999).
Medline CASGoogle Scholar
187 Shintani Y, Wheelock MJ, Johnson KR: Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol. Biol. Cell.17,2963–2975 (2006).
Medline CASGoogle Scholar
188 Ke Z, Lin H, Fan Z et al.: MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int. J. Cancer119,8–16 (2006).
Medline CASGoogle Scholar
189 Buck MB, Knabbe C: TGF-β signaling in breast cancer. Ann. NY Acad. Sci.1089,119–126 (2006).
Medline CASGoogle Scholar
190 Hanahan D, Weinberg RA: The hallmarks of cancer. Cell100,57–70 (2000).
Medline CASGoogle Scholar
191 Moreno-Bueno G, Portillo F, Cano A: Transcriptional regulation of cell polarity in EMT and cancer. Oncogene27,6958–6969 (2008).
Medline CASGoogle Scholar
192 Ikenouchi J, Matsuda M, Furuse M, Tsukita S: Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci.116,1959–1967 (2003).
Medline CASGoogle Scholar
193 Alexandrow MG, Kawabata M, Aakre M, Moses HL: Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of TGF-β. Proc. Natl Acad. Sci. USA92,3239–3243 (1995).▪ Established c-Myc as an a molecule that possesses anti-TGF-β activity during tumorigenesis.
Medline CASGoogle Scholar
194 Chen CR, Kang Y, Massague J: Defective repression of c-Myc in breast cancer cells: a loss at the core of the TGF-β growth arrest program. Proc. Natl Acad. Sci. USA98,992–999 (2001).
Medline CASGoogle Scholar
195 Smith AP, Verrecchia A, Faga G et al.: A positive role for Myc in TGF-β-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene28,422–430 (2008).
MedlineGoogle Scholar
196 Bromberg JF, Wrzeszczynska MH, Devgan G et al.: Stat3 as an oncogene. Cell98,295–303 (1999).
Medline CASGoogle Scholar
197 Yang Y, Pan X, Lei W et al.: Regulation of TGF-β1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res.66,8617–8624 (2006).
Medline CASGoogle Scholar
198 Zhao S, Venkatasubbarao K, Lazor JW et al.: Inhibition of STAT3Tyr705 phosphorylation by Smad4 suppresses TGF-β-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res.68,4221–4228 (2008).
Medline CASGoogle Scholar
199 Lo HW, Hsu SC, Xia W et al.: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res.67,9066–9076 (2007).
Medline CASGoogle Scholar
200 Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer2,101–112 (2002).
MedlineGoogle Scholar
201 Coombes RC, Gibson L, Hall E, Emson M, Bliss J: Aromatase inhibitors as adjuvant therapies in patients with breast cancer. J. Steroid Biochem. Mol. Biol.86,309–311 (2003).
Medline CASGoogle Scholar
202 Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA: MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell113,207–219 (2003).
Medline CASGoogle Scholar
203 Dhasarathy A, Kajita M, Wade PA: The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-α. Mol. Endocrinol.21,2907–2918 (2007).
Medline CASGoogle Scholar
204 Silveri L, Tilly G, Vilotte JL, Le Provost F: MicroRNA involvement in mammary gland development and breast cancer. Reprod. Nutr. Dev.46,549–556 (2006).
Medline CASGoogle Scholar
205 Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell122,6–7 (2005).
Medline CASGoogle Scholar
206 Iorio MV, Ferracin M, Liu CG et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65,7065–7070 (2005).
Medline CASGoogle Scholar
207 Blenkiron C, Miska EA: miRNAs in cancer: approaches, etiology, diagnostics and therapy. Hum. Mol. Genet.16,R106–R113 (2007).
Medline CASGoogle Scholar
208 Dalmay T, Edwards DR: MicroRNAs and the hallmarks of cancer. Oncogene25,6170–6175 (2006).
Medline CASGoogle Scholar
209 Blenkiron C, Goldstein LD, Thorne NP et al.: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol.8,R214 (2007).
MedlineGoogle Scholar
210 Hurteau GJ, Carlson JA, Spivack SD, Brock GJ: Overexpression of the microRNA Hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res.67,7972–7976 (2007).
Medline CASGoogle Scholar
211 Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEβ1 and ZEB2. J. Biol. Chem.283,14910–14914 (2008).
Medline CASGoogle Scholar
212 Gregory PA, Bert AG, Paterson EL et al.: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEβ1 and SIP1. Nat. Cell Biol.10,593–601 (2008).▪ Provide the first evidence linking altered microRNA expression to EMT stimulated by TGF-β.
Medline CASGoogle Scholar
213 Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEβ1 and ZEB2. Genes Dev.22,894–907 (2008).▪ Provide the first evidence linking altered microRNA expression to EMT stimulated by TGF-β.
Medline CASGoogle Scholar
214 Burk U, Schubert J, Wellner U et al.: A reciprocal repression between ZEβ1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep.9,582–589 (2008).▪ Provide the first evidence linking altered microRNA expression to EMT stimulated by TGF-β.
Medline CASGoogle Scholar
215 Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature449,682–688 (2007).
Medline CASGoogle Scholar
216 Kong W, Yang H, He L et al.: MicroRNA-155 is regulated by the TGF-β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol.28,6773–6784 (2008).
Medline CASGoogle Scholar
217 Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene26,2799–2803 (2007).
Medline CASGoogle Scholar
218 Zhu S, Si ML, Wu H, Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem.282,14328–14336 (2007).
Medline CASGoogle Scholar
219 Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res.18,350–359 (2008).
Medline CASGoogle Scholar
220 Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ: TGF-β and microRNA: mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs185,157–161 (2007).
Medline CASGoogle Scholar
221 Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H, Helfman DM: A critical role of tropomyosins in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol. Biol. Cell15,4682–4694 (2004).
Medline CASGoogle Scholar
222 Varga AE, Stourman NV, Zheng Q et al.: Silencing of the tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-β. Oncogene24,5043–5052 (2005).
Medline CASGoogle Scholar
223 Zheng Q, Safina A, Bakin AV: Role of high-molecular weight tropomyosins in TGF-β-mediated control of cell motility. Int. J. Cancer122,78–90 (2008).
Medline CASGoogle Scholar
224 Lombaerts M, van Wezel T, Philippo K et al.: E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer94,661 (2006).
Medline CASGoogle Scholar
225 Reynolds PA, Sigaroudinia M, Zardo G et al.: Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem.281,24790–24802 (2006).
Medline CASGoogle Scholar
226 Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD: Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl Acad Sci. USA105,14867–14872 (2008).
Medline CASGoogle Scholar
227 Singh M, Spoelstra NS, Jean A et al.: ZEβ1 expression in type I versus type II endometrial cancers: a marker of aggressive disease. Mod. Pathol.21,912 (2008).
Medline CASGoogle Scholar
228 Shackleton M, Vaillant F, Simpson KJ et al.: Generation of a functional mammary gland from a single stem cell. Nature439,84–88 (2006).
Medline CASGoogle Scholar
229 Stingl J, Raouf A, Eirew P, Eaves CJ: Deciphering the mammary epithelial cell hierarchy. Cell Cycle5,1519–1522 (2006).
Medline CASGoogle Scholar
230 Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L et al.: Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol.177,87–101 (2007).
Medline CASGoogle Scholar
231 Mishra L, Derynck R, Mishra B: TGF-β signaling in stem cells and cancer. Science310,68–71 (2005).
Medline CASGoogle Scholar
232 Ben-Porath I, Thomson MW, Carey VJ et al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet.40,499–507 (2008).
Medline CASGoogle Scholar
233 Mani SA, Guo W, Liao MJ et al.: The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell133,704–715 (2008).▪ Provides the first evidence linking EMT to the acquisition of ‘stemness’. Importantly, TGF-β signaling plays a major role in overseeing EMT and the appearance of cancer stem cells.
Medline CASGoogle Scholar
234 Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS ONE3,e2888 (2008).▪ Provides the first evidence linking EMT to the acquisition of ‘stemness’. Importantly, TGF-β signaling plays a major role in overseeing EMT and the appearance of cancer stem cells.
MedlineGoogle Scholar
235 Shipitsin M, Campbell LL, Argani P et al.: Molecular definition of breast tumor heterogeneity. Cancer Cell11,259–273 (2007).▪ Provides the first evidence linking EMT to the acquisition of ‘stemness’. Importantly, TGF-β signaling plays a major role in overseeing EMT and the appearance of cancer stem cells.
Medline CASGoogle Scholar
236 Farina AR, Coppa A, Tiberio A et al.: TGF-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int. J. Cancer.75,721–730 (1998).
Medline CASGoogle Scholar
237 Piek E, Ju WJ, Heyer J et al.: Functional characterization of TGF-β signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem.276,19945–19953 (2001).
Medline CASGoogle Scholar

Vol. 5, No. 8

Metrics

Downloaded 872 times

History

Published online 26 October 2009

Published in print October 2009

Information

Keywords

Acknowledgements

We thank members of the Schiemann Laboratory for critical comments and reading of the manuscript.

Financial & competing interests disclosure

William P Schiemann was supported by grants from the National Institutes of Health (CA114039 and CA129359), the Komen Foundation (BCTR0706967), and the Department of Defense (BC084651); Michael K Wendt was supported by the American Cancer Society (PF-09–120–101-CS); and Tressa M Allington was supported by the Department of Defense (BC083323). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Mechanisms of the epithelial–mesenchymal transition by TGF-β

Abstract

Bibliography